key: cord-0690019-rqzel8sd authors: Casari, Ilaria; Manfredi, Marcello; Metharom, Pat; Falasca, Marco title: Dissecting lipid metabolism alterations in SARS-CoV-2 date: 2021-02-08 journal: Prog Lipid Res DOI: 10.1016/j.plipres.2021.101092 sha: 81abf7ed5491d2f471a087b3058b8e5b9d85b268 doc_id: 690019 cord_uid: rqzel8sd Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the COVID-19 pandemic that has infected over sixteen million people globally. There have been more than two million deaths recorded worldwide, with no end in sight until a vaccine is developed. Current research has centred on different aspects of the virus interaction with cell surface receptors, but more needs to be done to further understand its mechanism of action in order to develop a targeted therapy and a method to control the spread of the virus. Lipids play a crucial role throughout the viral life cycle, and viruses are known to exploit lipid signalling and synthesis to affect host cell lipidome. Emerging studies using untargeted metabolomic and lipidomic approaches are providing new insight into the host response to COVID-19 infection. Indeed, metabolomic and lipidomic approaches have identified numerous circulating lipids that directly correlate to the severity of the disease, making lipid metabolism a potential therapeutic target. Circulating lipids play a key function in the pathogenesis of the virus and exert an inflammatory response. A better knowledge of lipid metabolism in the host-pathogen interaction will provide valuable insights into viral pathogenesis and to develop novel therapeutic targets. identified COVID-19-associated lipid biomarkers [12] . Moreover, lipid-lowering therapies such as statins and lipoprotein apheresis have been proposed as a therapeutic strategy to reduce clinical complications in patients severely affected by COVID-19 [13] . Increasing bioactive lipid levels has also been suggested as a method to reduce ACE2 receptors number and affinity to SARS-CoV-2 [14] . Therefore, targeting membrane sphingolipids and interfering with the virus lipid metabolism could represent a path to follow towards the development of COVID-19 treatments. Viruses are small, simple living organisms that survive only by invading host cells of animals, bacteria or plants and replicate within these cells, causing diseases during the process. They rely on the host cell for both their energy supply and metabolism. Viruses are divided according to their genetic characteristics [15] into two broad groups: DNA viruses and RNA viruses, and they can be "naked" or surrounded by an external layer composed of lipids, proteins and sometimes glycoproteins, called Even though viruses display different morphologies, ranging from a helical to Icosahedral, prolate, head or tail, complex or asymmetrical shape, these non-living particles depend on host organisms to survive and share a common basic structure. Three main elements concur to form a virus structure: 1) the nucleic acid, containing single or double-stranded DNA or RNA and enzymes for genetic transcription, which is between 5 to 200 kb in size; 2) a capsid surrounding this genetic material, a viral protective layer of proteins called "capsomeres" which gives the distinctive shape to the virus, and; 3) a glycoprotein envelope formed by a bilayer of lipids and proteins, essential for attaching to the host cell membrane and penetrating inside. Coronaviruses display on the envelope, as a distinctive feature, spike proteins that give the resemblance of a crown. SARS-CoV-2 particles (virions) are 125 nm wide spherical entities, with a characteristic crown on the surface, and a positive sense single-stranded RNA enveloped by a nucleocapsid, forming a symmetrical helical shape containing a large genome of 27-34 kb. Four structural proteins characterize this virus; the transmembrane spike protein (S protein) , the envelope protein (8) (9) (10) (11) (12) involved in the virion production and expulsion from the host cell, the membrane protein (25-30 kDa) responsible for the virion shape, all located in the envelope, and the nucleocapsid protein located inside the capsid and binding the RNA genome. Sixteen non-structural proteins are formed after the invasion of the host cell via open-reading frame (ORF) translation. The S protein has a homotrimeric conformation containing the receptor-binding domain S1 subunit, comprising, in turn, J o u r n a l P r e -p r o o f Journal Pre-proof an N-terminal domain (NTD) and a C-terminal domain (CTD), and the S2 subunit contributing to membrane fusion [17] . This protein allows SARS-CoV-2 virions to attach to host cell membrane receptors and, subsequently invade those cells. SARS-CoV-2 S1 subdomain CTD binds the ACE2 receptor on the surface of the host cell [18] . Unlike SARS-CoV, SARS-CoV-2 contains a polybasic furin cleavage site at the interface of the two subunits S1 and S2 of the spike protein [19] . Strikingly, this site is found in other pathogens such as Ebola, virulent bird flu strains, and HIV-1. When this site is cleaved by furin, the spike protein can interact with and activate an additional cell surface receptor, neuropilin 1 (NRP1). NRP1, when expressed together with ACE2, and type II transmembrane serine host cell protease (TMPRSS2), greatly potentiates viral entry and infection [20, 21] . Two different entry mechanisms are possible at this point; an early pathway in which virions blend at the plasma membrane, or a late pathway in which virions amalgamate at the endosomal membrane, according to proteases accessibility [22] . The early entry is mediated by TMPRSS2, which promotes viral fusion and nucleocapsid access into the cytoplasm by cleaving the S protein at the S1/S2 and S2' sites. For the late entry pathway, the virus is endocytosed, and the viral S protein is cleaved in the presence of cysteine protease cathepsin L before the genome being liberate into the host cell. In vivo studies have shown the importance of lipid rafts in facilitating coronaviruses entry in the host cells. In particular, cholesterol seems to play an essential role and, in its absence, both viral entry and fusion have been shown to be compromised [23] . Once in the cytoplasm, the virus exploits the host cell structures for genome replication; in the endoplasmic reticulum (ER) S protein constituents are produced, joined in the ER-Golgi intermediate compartment (ERGIC), the S protein is pre-cleaved and then released by exocytosis into the extracellular space. Lipids play a key role in the initial stages of the interaction of viruses with host membranes [24] . The very first step of this complex process is the virus adhesion to the cell membrane [25] . This involves unspecific binding with negatively charged sugars of glycoproteins and glycolipids that represents a first dock before the engagement with a specific receptor. Heparan sulphate proteoglycans, expressed by the majority of eukaryotic cells, have been shown to play a role in the adhesion of many viruses to the cell external membrane, including SARS-CoV-2 ( Figure 2 ). Indeed, a recent study demonstrated that SARS-CoV-2 spike protein interacts with both cellular heparan sulphate and ACE2 through its receptor-binding domain (RBD) domain [26] . In the latter study, the authors proposed a model in which viral attachment and infection involve heparan sulphate-dependent enhancement binding to ACE2 and consequently, inhibition of viral adhesion by exogenous heparin is suggested as a novel therapeutic approach [26] . A new insight into the SARS-CoV-2 pathogenicity is emerging from the recently published study by Toelzer et al., demonstrating a direct binding between fatty acids and SARS-CoV-2 proteins [27] . The authors used the cryo-electron microscopy technique to examine the spike glycoprotein structure of SARS-CoV-2. The analysis revealed the presence of three binding pockets in the receptor-binding domains (RBDs) firmly binding linoleic acid (LA). Further experiments confirmed the existence of these LA-binding sites in SARS-CoV and MERS-CoV. In in vitro experiments, this LA binding was found to cause a locked conformation of the spike protein resulting in a decreased association between this protein and ACE2 host receptor. Subsequently, human epithelial cells infected with SARS-CoV-2 were treated with different concentrations of Remdesivir, an anti-viral drug that has shown some effectiveness in COVID-19 clinical trials, in combination with LA. The addition of the latter resulted in a synergistic effect permitting a remarkable reduction of Remdesivir's dosage in order to block virus' replication. This finding could be a strategy to overcome the significant side effects observed in SARS-CoV-2 patients treated with Remdesivir [28] . Moreover, as fatty acid-binding pockets were used to developed anti-viral drugs successfully employed in clinical trials against rhinovirus [29] [30] [31] [32] , similarly, the discovery of LA-binding pockets could be exploited for designing specific inhibitors able to obstruct virus-host interactions by blocking the spike protein in the closed conformation. The subsequent step involves the virus entry into cell cytosol using either a direct fusion mechanism or the exploitation of the endocytic pathways of the host cells. In both cases, this is a critical energy-consuming stage involving viral membrane fusion. While enveloped virus entry through direct fusion with the plasma membrane appears to be the most convenient strategy, more recent evidence suggests that virus entry mostly occurs via endocytosis and that the use of the endosomal route provides multiple advantages [33] . Viruses have been shown to use different canonical and non-canonical endocytic pathways [34] . The canonical pathways involve the formation of clathrin-coated vesicles, whereas the non-canonical pathways require either caveolae, flotillin-1, glycophosphatidylinositol-anchored proteins or micropinocytosis. It has been found that SARS-CoV enters cells via an endocytosis pathway dependent on pH and receptor engagement but clathrin-and caveolae-independent [35] . In the latter study, it has been shown that cholesterol-and sphingolipid-rich lipid raft microdomains in the plasma membrane are involved in SARS-CoV entry [35] . However, further research is needed to confirm this mechanism of entry. Phosphoinositides (PtdIns) play critical roles in membrane dynamics, trafficking, and cellular signalling. In particular, the monophosphate phosphatidylinositol 3phosphate (PtdIns3P) and the bisphosphate phosphatidylinositol 3,5-bisphosphate [PtdIns(3,5)P 2 ] have been mostly linked with endosomes and endosomal functions [36] . Recent studies suggest that Ebola virus (EBOV) necessitates PtdIns(3,5)P 2 production in cells to support efficient transport to the receptor Niemann-Pick C1 (NPC1) that localizes in late endosomes and lysosomes [37] . Inhibition of PIKFYVE, the enzyme that phosphorylates PtdIns3P to produce PtdIns(3,5)P 2 , impeded colocalization of EBOV with NPC1 and induced virus concentration in intracellular vesicles with characteristics of early endosomes. Interestingly, other viruses such as Zaire ebolavirus and SARS-CoV-2 have been indicated to use analogous trafficking pathways for efficient entry. More importantly, PIKFYVE inhibitor Apilimod strongly impairs the infection of Zaire ebolavirus and SARS-CoV-2 suggesting the potential for targeting PIKFYVE in developing antiviral agents against SARS-CoV-2 [38] . Furthermore, inhibition of class III phosphoinositide 3-kinase (PI3K), the enzyme that produces PtdIns3P from PtdIns, has been shown to potently inhibit SARS-CoV-2 infection of human lung model ex vivo [39] . Similarly, class I PI3K inhibition has been shown to affect SARS-CoV-2 replication [40] . In addition, Type III phosphatidylinositol-4-kinase enzymes, that produce phosphatidylinositol-4phosphate, have been utilized in replication organelles by different viruses [41] . However, strategies aiming at the inhibition of PI-kinases should be taken with caution considering the potential side-effect that can be caused. In particular, J o u r n a l P r e -p r o o f Journal Pre-proof PIKFYVE inhibition has been shown to generate large vacuoles in cells and lead to apoptosis in vitro [42] and in vivo [43] . Cell Membranes perform essential functions of containment, signalling and molecule exchange that regulate all biological processes. Membrane lipid bilayers are asymmetrically modified by factors both internal and external, using the energy released by changing the membrane lipid composition, and from proteins composing the membrane or present in the cytoplasm. They can be curved inward (positively), in the process of endocytosis, or outward (negatively), generating extracellular vesicles [44] . Every +RNA virus, and coronaviruses among them, manipulate host cell membranes to build structures, termed viral replication organelles (RO), able to grant RNA synthesis and viral replication [45] . These structures, in addition to hijacking host factors, metabolites, lipids and proteins relevant to replication, may have a role in protecting the viral genetic material from being exposed to the host immune system [46] . Even though among distinct viruses there are great differences in the composition, structure and development of RO, they can be grouped into two main morphological categories; spherule formations and tubular and/or vesicular formations [47] . Spherule formations are membrane invaginations within host cell organelles, such as the ER, mitochondria and endolysosomes, not entirely separated from the cytosol to facilitate access to the required molecules and outdoor transport of vRNA. The second category includes host membrane protrusions forming tubular or vesicular organelles, amongst which, structures referred to as double-membrane vesicles (DMV) have attracted particular interest. Nidoviruses and coronaviruses, in particular, have been observed via electron tomography to produce a wide range of double-membrane formations, displaying a regular membrane interspace and various shapes such as zippered ER, convoluted membranes, open doublemembrane and double-membrane vesicles [48] . Studies on noroviruses DMVs have revealed membrane connections, called membrane contact sites (MCSs), in between vesicles, between DMVs and other structures of viral origins, and in particular between DMVs and ER, suggesting a fundamental role of the latter in DMV development [46, 47] . Viruses take control of these points of contact, which allow lipid trafficking between cytosol and RO, by interfering with cellular pathways or engaging MCS proteins, to ensure RO development and activity. Biogenesis of J o u r n a l P r e -p r o o f nidovirus DMV differs from other +RNA viruses. For some viruses, such as picornaviruses, a single membrane protrudes forming vesicles or tubules and subsequently the formation of paired membrane, two tightly placed lipid bilayers, is observed, forming cisternae that curve eventually giving shape to complete DMVs. In nidoviruses, including coronaviruses, membrane pairing occurs first in the ER, forming cisternae that will afterward curve and go through either one fission, generating a connected DMV, or two fissions to produce a disconnected floating DMV [46] . SARS-CoV non-structural proteins nsp3, nsp4 and nsp6 have been discovered to be essential for the biogenesis of double-membrane RO and viral RNA synthesis [48] . However, the complete understanding of the role of viral proteins in this process requires further studies. Another important element in viral biogenesis is the part played by host factors in supporting the virus life cycle. Regular cellular pathways in host cells are hijacked and exploited by viruses to survive and spread. For example, membrane proteins ER-associated reticulons and F-BAR domaincontaining proline-serine-threonine phosphatase-interacting protein 2 (PSTPIPP2) are thought to be instrumental in viral DMV establishment [49] . The autophagy and secretory pathways are also involved in this process as GBF1, a secretory protein, has been found to be correlated to DMV number in coronaviruses [50] . As essential membrane components and key factors regulating membrane curvature and DMV generation, lipids are also indispensable to coronaviruses development. Lysophospholipids (LPLs) levels have been found to be positively linked to coronaviruses DMV biosynthesis in in vitro studies [45] . Additionally, in the same study, an enzyme involved in lipid metabolism, cytosolic phospholipase A2cPLA2has been shown to affect coronavirus replication and DMV development. Lipidomic studies on human coronavirus-infected cells, using an ultra-high-performance liquid chromatography-mass spectrometry, revealed a significant modification in the host cell lipid composition upon infection, remarkably linked to coronavirus spreading [51] . Although the formation and function of DMV are beginning to be understood, there is still not enough evidence in regards to the intrinsic benefits of using such formations for viral RNA synthesis. Another open question is whether this process would still be possible without these structures, given that a few rare viruses, such as a mutant CVB3 enterovirus, are able to replicate without RO [52] . It has been hypothesized that RO might shield the virus genetic material from the immune system, and some studies support this theory [53] [54] [55] [56] [57] replication could occur safely inside by the inner membrane, while essential changes of metabolites would still be possible. On the other hand, completely exposed RO open structures, as in the case of picornaviruses, would not offer any protection. As for nidovirus, which has DMV close formations [46, 58] , material exchanges with the cytosol could take place via alternative routes, such as membrane pores, even though the exact location of RNA synthesis involving the inner membrane or the outer, or both, is not certain [46] . The release of the complete virions from the host cell is a little investigated aspect of SARS-CoV-2 replication cycle ( Figure 3 ). Recent work identified a novel mechanism of SARS-CoV-2 egress involving lysosomal exocytosis and not the biosynthetic secretory pathway generally utilized by enveloped viruses [59] . However, other investigators demonstrated the existence of two distinct egress pathways, using the cryo-imaging approach, involving tunnels via exocytosis release or through membrane rupture [60] . Therefore, further investigations are required to clarify this important step of SARS-CoV-2 cell infection cycle. After endocytosis, viruses establish their ideal niche and begins the first step of viral gene expression and then proceed to replication. One of the major targets in this stage is the manipulation of the metabolic state of the infected cell at different levels. Therefore, other than physical interaction with cellular membranes, viruses exploit and modulate lipid signalling and metabolism to benefit their replication. Indeed, lipids constitute not only the backbone of membranes but function as signalling molecules and energy sources. Therefore, reprogramming of lipid metabolism is a key feature of virus-host interaction [41] , similarly to the way cancer cells induce lipid reprogramming [61] . It should be noted that reprogramming of the host lipid metabolism could also be attributed to the host response to infection. Several studies found that viruses are able to enhance the expression and activity of critical enzymes in lipid biosynthesis. Among these key enzymes, there is a family of membrane-bound transcription factors in the endoplasmic reticulum, sterol regulatory J o u r n a l P r e -p r o o f element-binding proteins (SREBPs), which are critical in lipid regulation [62] . SREBPS are transcription factors that bind to promoters of genes involved in lipid biosynthesis, and consequently, they regulate cellular lipid metabolism and homeostasis. SREBPs are reported to be highly upregulated in Middle East respiratory syndrome coronavirus (MERS-CoV) and influenza A virus infections [63] . Lipid droplets (LDs), are lipid-rich cellular organelles that regulate lipid homeostasis and metabolism [64] . They serve as a store for cholesterol esters and triacylglycerols (TAGs) utilized for membrane formation and maintenance but also supply essential lipids to produce signalling molecules and metabolic energy. LDs also have a more dynamic role since proteins present in the lipid droplet coat regulate lipid homeostasis, and therefore, LDs play a very important role in the regulation of intracellular lipid storage and lipid metabolism [65] . Single-strand RNA viruses, including coronaviruses, target LDs during their replication phase [66, 67] . Given the role of LDs in viral replication, it has been proposed to use drugs interfering with LDs as therapeutics able to counteract SARS-CoV-2 infection [66, 68] LDs. In addition, they showed that the pharmacological inhibition of DGAT-1, which is a key enzyme for LD formation, reduced SARS-CoV2 replication, inflammatory mediator production and cell death, opening new therapeutic strategies [69] . Pathogens, and viruses among them, are obliged to find survival stratagems in order to avoid host defence mechanisms, successfully invade cells, replicate and spread. One of those strategies they rely on involves exploiting lipid microdomains, designated "lipid rafts", located primarily on the cell plasma membrane, but also reported in other internal organelles. Several diverse types of viruses, including coronaviruses, take advantage of these signal transduction platforms in order to J o u r n a l P r e -p r o o f penetrate inside cells during the fusion and internalization phase, for sending signals and transporting viral proteins, and also in the course of viral assembly before exocytosis [70] . Lipid rafts are specialized dynamic nanoscale regions, 10 and 200 nm in size, and consisting of sphingolipids, glycosphingolipids, cholesterol and GPIlinked proteins. They perform many tasks including, cell signalling, membrane trafficking, cell polarity regulation, polarized secretion, epithelial cells' transcellular transport, endocytosis and autophagy [70, 71] . In addition to their analogous lipoid composition, lipid rafts are also non-ionic detergent-insoluble, are isolated by sucrose density gradient, and are quick to change structure upon stimulation [72] [73] [74] . Their protein conformation determines whether lipid rafts are categorized as "planar", composed mainly of flotillin proteins, or "caveolae", enriched in caveolin proteins [75] , both mediating lipid raft signal transduction. The hypothesis of lipid rafts playing an essential role in pathogenic microbe invasion of host cells has been confirmed by numerous studies. Lipid raft disrupting or cholesterol-reducing/removing compounds, such as statins and methyl-β-cyclodextrin, were able to block pathological infections [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87, 88] . Given the prominent contribution of lipid rafts to virus survival and propagation, their therapeutic targeting could be a successful strategy to counteract infections [89] and, in particular, a valid tool in the fight against COVID-19 pandemic. Autophagy is a denomination derived from the Greek word meaning "self-eating"; it refers to a complex mechanism used routinely by cells to preserve homeostasis, J o u r n a l P r e -p r o o f which is enhanced in challenging conditions such as lack of nutrients or oxygen, stress, DNA damage, reactive oxygen species, or pathogenic infections [90, 91] . During this process, cellular parts, organelles and proteins are packed in autophagosomes, double-membrane vesicles that transport their content to the lysosome; autophagosomes fuse with the lysosome originating autolysosomes, where the cargo is processed and broken down by specific enzymes. ATG5 and ATG7 genes are autophagy regulators, and LC3 and p62 are the main proteins used as markers for autophagy. In fact, levels of LC3-II, lipidated LC3, are directly correlated to the number of autophagosomes in cells [92] thus showing the presence of autophagy; conversely, as p62 is degraded during this process, increased levels of this protein reveal autophagy inhibition and vice versa [93] . Strict cooperation has been shown to exist between lipid rafts and autophagy, as caveolin-1, a major component of plasma membrane lipid rafts, interferes with the expression of ATG12-ATG5, a conjugation system essential for autophagosome development [94] . In addition, autophagy seems to be affected by the same molecules involved in the chemical and structural configuration of lipid rafts [95] . Although autophagy has been shown to have a role in counteracting infections, transporting viral particles to lysosomes and boosting hosts' immune response, certain viruses are known to be able to neutralize lysosomal degradation and to utilize autophagy to survive and replicate [96] . Coyne et al. have found that cells that take up exosomes carrying microRNAs from placenta cells are very resistant to virus-induced autophagy [97] . Also, some virus replications can be limited by inducing autophagy, as in the case of Sindbis virus affecting the central nervous system in mice [98] . On the other hand, other viruses, such as herpesviruses, have found means of protecting themselves from autophagy degradation, by expressing proteins that impede autophagosomes development [99] . Many +RNA viruses, enteroviruses in particular, induce autophagy and exploit this mechanism to avail themselves of membranes necessary for the construction of their replication areas [100] . Nidovirales seems to have the ability to both employ autophagy-derived materials for their synthesis and to exploit autophagy mechanism to decrease viral degradation [101] . Conflicting results have been published regarding MERS-CoV, which has been described to induce autophagy by some authors [102] and to inhibit the same process by others [103] . Similarly, while it is known that SARS-CoV utilizes the autophagy pathway for replication [104, 105] , SARS-CoV-2 was recently J o u r n a l P r e -p r o o f discovered to decrease autophagy through AMPK and mTORC1 downregulation, with the advantage of limiting viral product degradation and profiting by the increase of double-membrane vesicles [106] . Some known autophagy promoters such as spermidine, niclosamide and nitazoxanide have been shown to have an effect against SARS-CoV-2 in in vitro studies [16, 107] and, as a consequence of these findings, the autophagy promoter rapamycin has been used in the clinical treatment of this infection, achieving some results (NCT04482712). CD49d, CD54 and CD11a proteins on the T-cell surface are exposed to CD81 and CD9 on exosome. In the antigen recognition mechanism, the major histocompatibility complex on exosomes is recognized and bound by T-cells. Virus and exosome biogenesis share evident similarities, and during infections viruses utilize the exosomal pathway to both enter cells and invade other tissues. Coronaviruses are similar in size to exosomes (about 125 nm), they both carry proteins and RNAs, and lipidomic studies on exosome membrane have found a remarkable resemblance with the composition of the virus membrane [111] . Viruses have been shown to modulate the production and molecular cargo of exosomes [112, 113] . Indeed, microRNAs, proteins and even intact virions can be packed into exosomes [113, 114] . Upon viral infection, host cells are activated to produce exosomes loaded with viral pro-inflammatory and cytotoxic molecules that are sent to nearby tissues where they induce inflammation, intravascular coagulation and trigger the endothelium causing sepsis and tissue damage. In a recent in vitro study, lung epithelial cells incorporated with SARS-CoV-2 genes were found to produce exosomes containing viral RNAs, and caused inflammation and viral genes uptake in human-induced pluripotent stem cell-derived cardiomyocytes they were put in contact with [115] . Moreover, our recent studies have confirmed the presence of SARS-CoV-2 RNA in circulating exosomes isolated from COVID-19 patients (provisionally accepted, 10 .3389/fmolb.2021.632290). Some studies suggested the possibility of SARS-CoV-2 using integrin as an additional receptor as its spike protein has been found to be able to bind integrins [116] . Similarly, tetraspanins, transmembrane glycoproteins abundant in exosomes and involved in their endocytosis mechanism, are known to be linked to certain viruses, including coronaviruses, and to be involved in several steps of their life cycle [117, 118] . Recent data support the importance of exosome trafficking in viral infections. In particular, the investigation of the interactome between 26 of the 29 SARS-CoV-2 proteins and human proteins revealed that 332 human proteins have a high confidence score of interaction [119] . Of those proteins, about 40% were found to be J o u r n a l P r e -p r o o f involved in vesicular trafficking pathways, including exosomes trafficking and lipid modification [119] . Strategies targeting exosome biogenesis and release, as a mechanism for SARS-CoV-2 spread, have been recently proposed [120, 121] . Many compounds have been shown to inhibit the release of exosomes such as calpeptin, Y27632, pantethine, imipramine, GW4869 (Figure 4) [122] . Further studies are required to validate the effects of these drugssingly and in combinationin preclinical models of SARS-CoV-2. The lipidomic study of biological biofluids obtained from patients is particularly challenging compared to the analysis performed at cellular levels. Therefore, before discussing the lipidomic studies performed in humans, we will briefly give an overview of all issues and obstacles that investigators face in this field, especially considering the complications related to handling infected materials. This is an outline of lipidomics approaches to study SARS-CoV-2 infection and COVID-19 pathogenesis. Blood is a biological fluid that can be easily collected with minimal health risk. Its composition reflects human physiology in health and disease but also metabolism aspects. Plasma and serum, which are rich in lipids, are widely used for lipid biomarker discovery [123] [124] [125] [126] [127] . Plasma and serum are two distinct matrices; plasma is the liquid that remains when clotting is arrested with the introduction of an anticoagulant, while serum is obtained after blood has clotted. Thus, their lipid profiles differ even when obtained from the same blood draw [128, 129] . For lipidomic research, the use of plasma is recommended. Plasma is the closest matrix to blood plasma in vivo, and it is better for robustness, for comparing and interpreting physiological conditions. The coagulation process involved in serum preparation leads to the generation or degradation of molecules, including lipids. This process affects the abundances of LPLs, sphingosine 1-phosphate (S1P), prostaglandins, leukotrienes, resolvins, oxylipins and other lipid species [130] . In clinical practice, the serum is largely used and therefore, may be more appropriate The containers utilized for sample collection should be airtight to avoid sublimation, which can also impair sample concentrations [131] . Preparing aliquots immediately after plasma/serum isolation will contribute to limit freeze-thaw cycles that may affect the abundance of specific lipid classes. Sample stability is very important for lipidomic analysis [132] . Samples should be immediately processed or frozen because enzymatic and chemical processes can metabolize lipids. This is particularly important when oxidation products like oxidized phospholipids, oxylipins, and lysolipids are analysed. Samples should be stored at −80 °C, and the storage time should be as short as possible. Sample homogenization is another important step for the analysis of cells. This procedure ensures a more efficient lipid extraction by rupturing the plasma membrane and access to intracellular domains. Cells can be disrupted by using cold sonication, a pebble mill with beads or a nitrogen cavitation bomb [133, 134] . Sample manipulation of SARS-CoV-2 infected material must be performed using appropriate biosafety level containment laboratories until pathogen inactivation. For example, Burnum-Johnson et al. observed the total deactivation of both bacterial and viral pathogens with exposed lipid envelopes, including MERS-CoV, proposing a procedure for concomitant pathogen inactivation and extraction of samples for multiomics profiling [135] . For lipidomic analysis, the sample could be considered safe after the addition of an alcoholic solution, which is usually employed for protein precipitations and lipid extraction. The role of lipids in COVID-19 has been investigated especially on bio-fluids from infected patients. Several studies reported the involvement of lipids and lipid metabolism (Table 1) well as inflammatory responses [139] . The involvement of glycerophospholipids and fatty acids such as arachidonic acid have been reported in HCoV-229E-infected cells and MERS-CoV replication [51] , while the down-regulation of choline and its derivatives and the up-regulation of phosphocholine, were associated to activated macrophage-mediated immunity [140] . The overall down-regulation of serum lipids in COVID-19 patients is linked to liver damage, which is supported by changes in bilirubin and bile acids. Lipids alterations were also reported in a cohort of Chinese patients with COVID-19 [137] . General dyslipidaemia was observed using a targeted metabolomic and consequence of infection, converting TAG to NEFA and DAG, but also enhancing the recycling of fatty acids back into TAGs [141] . Phosphatidylcholines (PCs) were constantly decreased during the course of COVID-19 fatal cases. The reduction of specific immune regulatory lipid mediators (LMs) and the augmentation of pro-inflammatory species from moderate to severe COVID-19 disease was reported in a study that involved 19 healthy patients, 18 COVID-19 patients who did not need ICU admission (moderate) and 20 patients that needed ICU admission (severe) [141] . An increase of free PUFAs and diminished amounts of PUFA-containing plasmalogens were reported [141] . The authors were able to identify an over-expression of the C20:4 series through the classification of lipids Finally, lipids alterations were detected using NMR spectroscopy by Bruzzone et al. [146] . The authors analysed 263 symptomatic patients, and they found a pathogenic rearrangement of the lipoprotein particle size and composition. Patients were characterized by increased amount of ketone bodies like acetoacetic acid, 3hydroxybutyric acid and acetone, but also of 2-hydroxybutyric acid, a reflection of hepatic glutathione synthesis and marker of oxidative stress. Authors suggested that serum accumulation of TAG and TAG-VLDL (VLDL, very low-density lipoproteins) in COVID-19 patients might be a consequence of the decreased hepatic ability to oxidize acetyl-CoA in the mitochondria. In fact, ketone bodies are mainly synthesized in the liver from fatty acid oxidation-derived acetyl-CoA. To sum up, lipid alterations exhibited a correlation with the gravity of the disease, suggesting that the development of the infection influenced whole-body metabolism and specifically lipid metabolism. In addition, the balance between immuneregulating lipids, pro-inflammatory lipids and lipid mediators can modulate the immune response during COVID-19 disease. Based on the literature on COVID-19 disease, it is evident that lipid metabolism has a key role in SARS-CoV-2 infection. This is supported not only by lipidomic results, but also by the strong involvement of apolipoproteins and steroid hormones. A decrease of apolipoproteins APOA1, APOA2, APOH, APOL1, APOD, and APOM was identified after the infection [136] , while APOA1 underexpression was reported through the transition of COVID-19 patients from mild to severe disease [147] . Most J o u r n a l P r e -p r o o f of these apolipoproteins are associated with macrophage functions, which is closely related to lipid metabolism. The augmentation of steroid hormones, which can stimulate the activity of macrophages, was also shown [136, 138] . In addition, Song et al. [137] Dysregulations of lipid metabolism resulted in exceedingly drastic changes in fatal COVID-19 cases than in survivors, as reported by Wu et al [148] . Interestingly, patients hospitalized with either severe or mild symptoms, showed abnormal lipid profiles long after major clinical signs had disappeared. It has already been shown that, in severe COVID-19 inflammation, arachidonic acid is involved in the production of cytokines, causing a cytokine storm [149, 150] [146] . At the same time, the total cholesterol (TC) was decreased. All these examinations imply a remodelling of the lipoprotein particle phenotype in COVID-19 patients, and thus of a great part of circulating lipids. In consequence, these observations denote an augmented cardiovascular risk for COVID-19 patients [146] . J o u r n a l P r e -p r o o f The identification of potential biomarkers for the identification of COVID-19 disease is a challenge that could be overcome using mass spectrometry. Shen et al. investigated the potentiality of characterizing the severity of COVID-19 patients based on the molecular signatures of proteins and metabolites [136] . They employed machine learning models on selected proteins (22) and metabolites (7) suggesting the targeting of liver activity as therapeutic strategy [146, 148] . Dyslipidaemia is a group of diverse abnormal blood lipid conditions outside of the normal rangegenerally describing hypercholesterolemia, elevated LDL cholesterol, reduced HDL cholesterol and hypertriglyceridemiathat promote atherosclerosis [157, 158] . Dyslipidaemia can be separated into two broad categories, primary and apolipoprotein A-I levels [161, 162] , and low HDL and increased serum triglyceride levels, respectively. Similarly, the reduction of these lipoproteins is observed during infections, and are predictive of severity and mortality [163] [164] [165] . Thus, it is not surprising that COVID-19 patients showed worsen hypolipidaemia in association with the disease progression and severity of the symptoms [12, 166, 167] . Table 2 summarises several COVID-10 associated dyslipidaemia studies. Although cholesterol may be a predictive marker of poor outcome for COVID-19 infection, the exact molecular mechanism underpinning the functional role of lipids during SARS-CoV-2 infection is still not completely understood. Two large epidemiological studies recently described an increased risk of infection-related hospitalizations with low HDL-c levels [168, 169] , which support several previous findings that HDL-c has an essential part in host defence, including anti-thrombotic [170] [171] [172] , anti-oxidant [173, 174] and anti-inflammatory [170, 175, 176] properties. While there is not enough evidence to suggest that a reduced cholesterol level is the direct contributory factor in, or cause of, SARS-CoV-2 susceptibility, calls to examine cholesterol as a therapeutic target are gaining momentum [177, 178] . Stemmed from retrospective analyses that showed COVID-19 patients on statins had better outcome [179, 180] , a yet to be peer-reviewed in vitro study by Moeller et al. suggests a decreased rate of SARS-CoV-2 infection under statin treatment, possibly due to reduced membrane cholesterol impacting ACE2-viral spike protein interactions [181] . thrombocytopenia (low platelet count), information readily obtained from routine blood analysis, are predictive of COVID-19 severity and mortality [182] [183] [184] [185] . Similarly, coagulation tests for increased plasma D-dimers, fibrinogen degradation products and prothrombin time (time required for blood plasma to clot) are associated with morbidity and death [186] [187] [188] [189] . [187] . DIC can be triggered by infection, injury or certain types of cancer, through the extrinsic coagulation pathway when blood is exposed to tissue factor, commonly, on injured endothelium. Although there are some similar laboratory parameters, COVID-19-associated coagulopathy is quite different from DIC [190] . COVID-19 patients often suffer thrombotic complications rather than DIC-associated bleeding issues. Al-Samkeri et al. reported 9.5% overall thrombotic complication rate (approximately half of these individuals had confirmed venous thromboembolism (VTE), while 4.8% of patients showed overall bleeding event [191] . Thus, anticoagulants are increasingly being recommended by expert groups to treat hospitalized COVID-19 and critically ill patients [192, 193] . The haemostatic system is complex and highly regulated interactions between the vessel wall, platelets, and plasma proteins, all of which lipids are acknowledged as essential components [194] [195] [196] [197] . For example, oxidized LDL and VLDL can act as a surface to support prothrombinase complex activity and, other reactions within the coagulation cascade [198, 199] . However, one group of lipid-associated proteins are receiving increased attention during COVID-19 pandemic. The activity of enzymes of the family PLA2 is well known to be significantly elevated during inflammation and infection, including by SARS-CoV [200] [201] [202] . During viral infection, especially with positive-RNA viruses, the PLA2 activity has been demonstrated to reflect the remodelling of the host cellular membrane structure to accommodate viral replication [45, 203, 204] . PLA2 catalyses the cleavage of membrane glycerophospholipids, producing LPLs and fatty acids J o u r n a l P r e -p r o o f ( Figure 5 ). There are more than 30 PLA2s or related enzymes in mammalian cells, which are subdivided into three major families, the cytosolic cPLA2 and the extracellular or secretory sPLA2 ( Figure 5 ) [205] . PLA2-generated products such as AA and lysophospholipids are crucial in the biosynthesis of potent cellular mediators; eicosanoids and platelet-activating factor [206, 207] . In the context of coagulation and thrombosis, the products of PLA2 are highly relevant. The phospholipid plateletactivating factor (PAF) is an agonist of platelet activation and aggregation [208, 209] . PAF can also stimulate neutrophils to release neutrophil extracellular trap (NET), a mesh of proteins and DNA that is capable of initiating the coagulation cascade, platelet aggregation and thrombosis [210] [211] [212] [213] . Similarly, AA and its eicosanoid products, such as thromboxane A2, have platelet-activating effects [214, 215] . Indeed, increased platelet activity, hypercoagulability, and NET markers have been detected in COVID-19 patients with thrombotic complications [216] [217] [218] [219] . It remains to be investigated whether targeting virus-induced lipid dysfunction by inhibiting PLA2 activation is a useful strategy to ameliorate inflammation and clotting issues. SARS-CoV-2 is the cause of the COVID-19 pandemic that has infected about a hundred million people globally (as of January 21 st , 2021). In the last few months, an unprecedented scientific effort has been directed at studying COVID-19, particularly in examining its peculiar capacity to attack many different types of human cells and what drives its unusually high mortality rate [220] . An effective research approach is urgently needed to further understand the mechanism of action of this virus in order to develop a targeted therapy and a method to control its spreading. Different therapeutical approaches have been tried, using antiviral such as Remdesivir, corticosteroids or monoclonal antibodies, with marginal success in some cases, but a specific cure targeting this virus and impeding the occurrence of health complications for patients is yet to be found. In particular, it is currently impossible to anticipate the prognosis for infected patients and so the few treatments available start usually at a late stage when patients are already in critical conditions. Thus, the possibility of early treatment is currently hindered. Viruses are known to exploit the host resource and machinery, particularly lipid metabolism pathways, to invade cells and replicate. Therefore, therapeutic approaches targeting conserved cellular mechanism that virus manipulates to enter host cells and replicate are particularly attractive. Strategies to specifically target lipid metabolism have been tried, such as J o u r n a l P r e -p r o o f the use of cholesterol depleting agents or autophagy inducers. One way of responding in a short time frame and avoiding severe adverse effects is to look to drugs that have received approval to treat other diseases. Unfortunately, given the frequency of viral epidemics that we have witnessed in the last decade (SARS, MERS, HIV/AIDS, H1N1, Ebola virus etc.), it is likely that we will see the appearance of a new pandemic in the near future. Consequently, a therapeutical approach to COVID-19 that can be adapted and exploited in the event of future outbreaks is urgently needed. Vaccine or antibodies, if successfully developed, will be specific for SARS-CoV-2 and are unlikely to be useful in protecting against other viruses [221] . Therefore, a more general strategy to block virus spread, such as drugs targeting key steps in lipid metabolism, has the potential to be extended to counteract other viral infections. The authors have no competing interests to declare. Escaping Pandora's Box -Another Novel Coronavirus World Health Organization, WHO Director-General's opening remarks at the media briefing on COVID-19 Coronavirus: three things all governments and their science advisers must do now Critics of Sweden's lax pandemic policies face fierce backlash CRC), COVID-19 data in motion Discovering drugs to treat coronavirus disease 2019 (COVID-19) How does SARS-CoV-2 cause COVID-19? COVID-19 transmission through asymptomatic carriers is a challenge to containment, Influenza Other Respir Viruses Face masks for the public during the covid-19 crisis COVID-19 and the cardiovascular system The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection Cardiovascular diseases, lipid-lowering therapies and European registries in the COVID-19 pandemic Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion Global Organization and Proposed Megataxonomy of the Virus World Repurposing old drugs as antiviral agents for coronaviruses Coronavirus membrane fusion mechanism offers a potential target for antiviral development Structural basis of receptor recognition by SARS-CoV-2 Cell entry mechanisms of SARS-CoV-2 Neuropilin-1 is a host factor for SARS-CoV-2 infection Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity Cholesterol in Relation to COVID-19: Should We Care about It? Lipid Tales of Viral Replication and Transmission Targeting viral entry as a strategy for broad-spectrum antivirals SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2 Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein Remdesivir for the Treatment of Covid-19 -Preliminary Report Structural analysis of a series of antiviral agents complexed with human rhinovirus 14 The structure of human rhinovirus 16 Antiviral therapeutic approaches for human rhinovirus infections Rhinovirus -From bench to bedside Role of lipids in virus replication Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway Analysis, regulation, and roles of endosomal phosphoinositides Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2 Suppression of SARS-CoV-2 infection in ex-vivo human lung tissues by targeting class III phosphoinositide 3-kinase Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication Inhibition of PIKfyve by YM-201636 dysregulates autophagy and leads to apoptosis-independent neuronal cell death Loss of PIKfyve in platelets causes a lysosomal disease leading to inflammation and thrombosis in mice Membrane curvature in cell biology: An integration of molecular mechanisms Inhibition of Cytosolic Phospholipase A(2)α Impairs an Early Step of Coronavirus Replication in Cell Culture Double-Membrane Vesicles as Platforms for Viral Replication Building Viral Replication Organelles: Close Encounters of the Membrane Types New insights on the role of paired membrane structures in coronavirus replication Proline-serinethreonine phosphatase-interacting protein 2 (PSTPIP2), a host membrane-deforming protein, is critical for membranous web formation in hepatitis C virus replication Mouse hepatitis coronavirus RNA replication depends on GBF1-mediated ARF1 activation Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication The Hepatitis C Virus-Induced Membranous Web and Associated Nuclear Transport Machinery Limit Access of Pattern Recognition Receptors to Viral Replication Sites Quantitative analysis of the hepatitis C virus replication complex RNA replication of mouse hepatitis virus takes place at double-membrane vesicles Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment Replicase-mediated shielding of the poliovirus replicative double-stranded RNA to avoid recognition by MDA5 SARS-coronavirus replication/transcription complexes are membrane-protected and need a host factor for activity in vitro A unifying structural and functional model of the coronavirus replication organelle: Tracking down RNA synthesis N. Altan-Bonnet, β-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway SARS-CoV-2 Assembly and Egress Pathway Revealed by Correlative Multi-modal Multi-scale Cryoimaging, bioRxiv The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2 SREBP-regulated lipid metabolism: convergent physiologydivergent pathophysiology SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target Lipid Droplets: Formation to Breakdown Protein Quality Control and Lipid Droplet Metabolism ssRNA Virus and Host Lipid Rearrangements: Is There a Role for Lipid Droplets in SARS-CoV-2 Infection? Mammalian lipid droplets are innate immune hubs integrating cell metabolism and host defense The hypothetical role of phosphatidic acid in subverting ER membranes during SARS-CoV infection Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators Microbial pathogenesis: lipid rafts as pathogen portals Lipid rafts as a membrane-organizing principle Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells Lipid rafts and signal transduction Lipid rafts and detergent-resistant membranes in epithelial keratinocytes Human coronavirus 229E binds to CD13 in rafts and enters the cell through caveolae Murine coronavirus requires lipid rafts for virus entry and cell-cell fusion but not for virus release Membrane rafts in host-pathogen interactions Lipid rafts are involved in SARS-CoV entry into Vero E6 cells Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity? Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection Statins: Could an old friend help in the fight against COVID-19? Cholesterol of lipid rafts is a key determinant for entry and post-entry control of porcine rotavirus infection Cellular Cholesterol Facilitates the Postentry Replication Cycle of Herpes Simplex Virus 1 Cholesterol effectively blocks entry of flavivirus Lipophilic statins inhibit Zika virus production in Vero cells Coronaviruses: an overview of their replication and pathogenesis Coronavirus Interplay With Lipid Rafts and Autophagy Unveils Promising Therapeutic Targets Lipid rafts as a therapeutic target Eaten alive: a history of macroautophagy Autophagy and the integrated stress response LC3-positive structures are prominent in autophagy-deficient cells Monitoring autophagic degradation of p62/SQSTM1 Autophagy and Viral Infection A Comprehensive Review of Autophagy and Its Various Roles in Infectious, Non-Infectious, and Lifestyle Diseases: Current Knowledge and Prospects for Disease Prevention Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance Human placental trophoblasts confer viral resistance to recipient cells Autophagy protects against Sindbis virus infection of the central nervous system Autophagy, immunity, and microbial adaptations Subversion of cellular autophagosomal machinery by RNA viruses The Interaction between Nidovirales and Autophagy Components Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection Glycogen synthase kinase-3 regulates the phosphorylation of severe acute respiratory syndrome coronavirus nucleocapsid protein and viral replication Coronavirus nucleocapsid protein facilitates template switching and is required for efficient transcription Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206 Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications Proteomics analysis of bladder cancer exosomes Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation Lipids in exosomes: Current knowledge and the way forward Extracellular vesicles in virus infection and pathogenesis Viral effects on the content and function of extracellular vesicles Extracellular vesicles: Vehicles of en bloc viral transmission The Global Phosphorylation Landscape of SARS-CoV-2 Infection A potential role for integrins in host cell entry by SARS-CoV-2 Coronavirus and influenza virus proteolytic priming takes place in tetraspanin-enriched membrane microdomains Tetraspanins in viral infections: a fundamental role in viral biology? A SARS-CoV-2 protein interaction map reveals targets for drug repurposing Inhibiting Extracellular Vesicle Trafficking as Antiviral Approach to Corona Virus Disease Mechanisms of COVID-19-induced cardiovascular disease: Is sepsis or exosome the missing link? Inhibiting extracellular vesicles formation and release: a review of EV inhibitors The human plasma lipidome Applications of mass spectrometry to lipids and membranes Lipidomics: Techniques, Applications, and Outcomes Related to Biomedical Sciences Biomarkers of NAFLD progression: a lipidomics approach to an epidemic Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis Differences between human plasma and serum metabolite profiles Serum or plasma, what is the difference? Investigations to facilitate the sample material selection decision making process for metabolomics studies and beyond Sphingosine 1-phosphate release from platelets during clot formation: close correlation between platelet count and serum sphingosine 1-phosphate concentration The Impact of Sample Storage Time on Estimates of Association in Biomarker Discovery Studies A Review of Efforts to Improve Lipid Stability during Sample Preparation and Standardization Efforts to Ensure Accuracy in the Reporting of Lipid Measurements Analytical Techniques in Lipidomics: State of the Art Optimization of lipid extraction from the oleaginous yeasts Rhodotorula glutinis and Lipomyces kononenkoae MPLEx: a method for simultaneous pathogen inactivation and extraction of samples for multi-omics profiling Proteomic and Metabolomic Characterization of COVID-19 Patient Sera Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status Sphingolipids and their metabolism in physiology and disease Choline Uptake and Metabolism Modulate Macrophage IL-1β and IL-18 Severe SARS-CoV-2 infection in humans is defined by a shift in the serum lipidome resulting in dysregulation of eicosanoid immune mediators, medRxiv Eicosanoid storm in infection and inflammation Phospholipase A2 regulates eicosanoid class switching during inflammasome activation Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2 Large-Scale Multi-omic Analysis of COVID-19 Severity SARS-CoV-2 Infection Dysregulates the Metabolomic and Lipidomic Profiles of Serum, iScience Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study, medRxiv Mass Spectrometry-based Lipidomics and Its Application to Biomedical Research Can Bioactive Lipids Inactivate Coronavirus (COVID-19)? The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system Use of focused open vessel microwave-assisted extraction as prelude for the determination of the fatty acid profile of fish -a comparison with results obtained after liquid-liquid extraction according to Bligh and Dyer An improved SPE method for fractionation and identification of phospholipids Multifaceted roles for lipids in viral infection Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection May omega-3 fatty acid dietary supplementation help reduce severe complications in Covid-19 patients? Omega 3 Fatty Acids and COVID-19: A Comprehensive Review Dyslipidemia in type II diabetes. Implications for therapeutic intervention The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome Genetics and Dyslipidemia Plasma lipoproteins: genetic influences and clinical implications Lipid profiles among US elderly with untreated rheumatoid arthritis--the Third National Health and Nutrition Examination Survey Dyslipoproteinemia in the course of active rheumatoid arthritis Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation Prognostic impact of plasma lipids in patients with lower respiratory tract infections -an observational study Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis Hypolipidemia is associated with the severity of COVID-19 Letter to the Editor: Lowdensity lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease Causal Inference for Genetically Determined Levels of High-Density Lipoprotein Cholesterol and Risk of Infectious Disease Ushaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans High-density lipoprotein as a modulator of platelet and coagulation responses Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis The protective effects of HDL and its constituents against neutrophil respiratory burst activation by hypochlorite-oxidized LDL Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia High-density lipoprotein mediates antiinflammatory reprogramming of macrophages via the transcriptional regulator ATF3 Statin therapy in COVID-19 infection Cholesterol-modifying drugs in COVID-19 Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 Effect of statins on SARS-CoV-2 infection Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study COVID-19 Infection and Haematological Involvement: a Review of Epidemiology, Pathophysiology and Prognosis of Full Blood Count Findings Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19 More on COVID-19 coagulopathy in Caucasian patients Hemostatic Abnormalities in COVID-19: An Update COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory ISTH interim guidance on recognition and management of coagulopathy in COVID-19 Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk Networks of enzymatically oxidized membrane lipids support calcium-dependent coagulation factor binding to maintain hemostasis Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E Multiple roles of phospholipase A2 during lung infection and inflammation Cytosolic Phospholipase A(2)α Promotes Pulmonary Inflammation and Systemic Disease during Streptococcus pneumoniae Infection Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection Cytosolic phospholipase A2 gamma is involved in hepatitis C virus replication and assembly Phospholipase A2 activity during the replication cycle of the flavivirus West Nile virus Recent progress in phospholipase A₂ research: from cells to animals to humans Toward understanding interfacial activation of secretory phospholipase A2 (PLA2): membrane surface properties and membrane-induced structural changes in the enzyme contribute synergistically to PLA2 activation Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? The role of platelet-activating factor in platelet aggregation Role of platelet-activating factor in aggregation of leukocytes and platelets in cerebral ischemia Pancreatic Cancer-Induced Neutrophil Extracellular Traps: A Potential Contributor to Cancer-Associated Thrombosis Neutrophil extracellular traps induce aggregation of washed human platelets independently of extracellular DNA and histones Impaired neutrophil extracellular trap (NET) formation: a novel innate immune deficiency of human neonates Extracellular DNA traps promote thrombosis Platelet aggregation induced by arachidonic acid is accompanied by release of potential inflammatory mediators distinct from PGE2 and PGF2 Role of arachidonic acid metabolism in human platelet activation and irreversible aggregation Platelet gene expression and function in patients with COVID-19 Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19 Vascular occlusion by neutrophil extracellular traps in COVID-19 SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes Covid-19: Experts advise cautious optimism for neutralising antibodies after early results Plasma polyunsaturated fatty acids and periodontal recovery in Taiwanese with periodontitis: a significant relationship COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm This work was partially supported by the AGING Project -Department of Excellence -DIMET, Università del Piemonte Orientale", MIUR ITALY to MM. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Figures were created with BioRender.com.